Oxidation and ubiquitination in neurodegeneration

Experimental Biology and Medicine

Volumn 238, Issue 5, 2013, Pages 519-524

  Riederer, Beat M ^a,b   Leuba, Geneviève ^a   ElHajj, Zeinab ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Alzheimer's disease; Mitochondria; Neurodegeneration; Oxidation; Tau protein; Ubiquitination

Indexed keywords

LIPOFUSCIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEASOME;

AGGRESOME; ARTICLE; AUTOPHAGY; COGNITION; DNA DAMAGE; ENERGY TRANSFER; EXCITOTOXICITY; FLUORESCENCE MICROSCOPY; GLIOSIS; HUMAN; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PROTEIN DEGRADATION; RISK FACTOR; UBIQUITINATION;

ALZHEIMER'S DISEASE; MITOCHONDRIA; NEURODEGENERATION; OXIDATION; TAU PROTEIN; UBIQUITINATION;

AGING; LYSOSOMES; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; UBIQUITIN; UBIQUITINATION;

EID: 84881599223     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213488484     Document Type: Article

References (64)

1. Stadtman ER. Protein oxidation and aging. Free Rad Res 2006;40:1250-8.
2. Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp Biol Med 2011;236:268-76.
3. Gupta SC, Kim JH, Kannappan R, Reuter S, Dougherty PM, Aggarwal BB. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med 2011;236:658-71.
4. Ihara Y, Morishima-Kawashima M, Nixon R. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. CSH Persp Med 2012;2:a006361.
5. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009;417:1-13.
6. Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993;43:192-7.
7. Anderton BH. Ageing of the brain. Mech Ageing Devel 2002;123:811-17.
8. Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alz Dis 2005;7:103-17.
9. Baloyannis SJ. Mitochondria are related to synaptic pathology in Alzheimer's disease. Int J Alz Dis 2011;2011:1-7.
10. Du H, Guo L, Yan SS. Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid Redox Signal 2012;16:1467-75.
11. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 2012;1822:639-49.
12. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodeg 2011;6:1-14.
13. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick RP, Carlson GA, Lanier LM, Yuan L-L, Ashe KH, Liao D. Tau mislocalzation to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010;68:1067-81.
14. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutiunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010;67:953-66.
15. Mandelkow E-M, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. CSH Perspect Med 2012;2:a006247.
16. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, Palop JJ, Noebels JL, Mucke L. Amyloid-ß/Fyninduced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 2011;31:700-11.
17. Lipton SA, Choi Y-B, Takahashi H, Zhang D, Li W, Godzik A, Bankston LA. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends Neurosci 2002;25:474-80.
18. Nakamura T, Lipton SA. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ 2011;18:1478-86.
19. von Bernhardi R, Eugenin J. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 2012;16:974-1031.
20. Lee C, Yu M-H. Protein folding and disease. J Biochem Mol Biol 2005;38:275-80.
21. Zouambia M, Fischer DF, Hobo B, De Vos RA, Hol EM, Varndell IM, Sheppard PW, Van Leeuwen FW. Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: consequences for proteomic analyses. Proteomics 2008;8:1221-36.
22. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 2006;545:39-50.
23. Schulenborg T, Schmidt O, van Hall A, Meyer HE, Hamacher M, Marcus K. Proteomics in neurodegeneration - disease driven approaches. J Neural Transm 2006;113:1055-73.
24. Martinez A, Portero-Otin M, Pamplona R, Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 2010;20:281-97.
25. Seehafer SS, Pearce DA. You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol Aging 2006;27:576-88.
26. Mecocci P, Polidori MC. Antioxidant clinical trails in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 2012;1822:631-8.
27. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009;7:65-74.
28. Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, Gokhman D, Gasiorowski K, Bragin V, Aliev G. Mitochondrion-specific anti-oxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets 2011;10:149-62.
29. Gomez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev 2008;9:568-78.
30. Riederer BM. Oxidation proteomics: the role of thiol modifications. Curr Proteomics 2009;6:51-62.
31. Dikshit P, Goswami A, Mishra A, Nukina N, Jana NR. Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin- induced cell death by promoting proteasomal malfunction. Biochem Biophys Res Comm 2006;342:1323-8.
32. Tai H-C, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 2008;9:826-38.
33. Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009;118:329-47.
34. Olzmann JA, Chin LS. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 2008;15:47-60.
35. Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochem Biophys Acta 2005;1739:298-310.
36. Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, Murata S, Tanaka K, Takashima A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 2005;94:1254-63.
37. Castellani RJ, Nunomura A, Lee H-G, Perry G, Smith MA. Phosphorylated tau: toxic, protective, or non of the above. J Alz Dis 2008;14:377-83.
38. Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol 2007;62:553-9.
39. Muñoz P, Huenchuguala S, Paris I, Segura-Aguilar J. Dopamine oxidation and autophagy. Parkinsons Dis 2012;2012:1-13.
40. Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012;181:1426-35.
41. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, LeVine H, Lott IT, Schmitt FA, Butterfield DA, Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 2012;1822:130-8.
42. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010;69:155-67.
43. Setsuie R, Wada A. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 2007;51:105-11.
44. Gong B, Cao Z, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O. Ubiquitin hydrolase Uch-L1 rescues betaamyloid- induced decreases in synaptic function and contextual memory. Cell 2006;126:775-88.
45. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L. Oxidative modifications and down-regulation of ubiquitin carboxylterminal hydrolase L1 associated with idiopathic Parkinsons's disease and Alzheimer's disease. J Biol Chem 2004;279:13256-64.
46. de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Progr Neurobiol 2004;74:249-70.
47. Gao X, Hu H. Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin 2008;40:612-18.
48. Yen SS. Proteasome degradation of brain cytosolic tau in Alzheimer's disease. Int J Clin Exp Pathol 2011;4:385-402.
49. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003;85:115-22.
50. Haass C, Mandelkow E. Fyn-tau-amyloid: a toxic triad. Cell 2010;142:356-8.
51. ElHajj Z, Riederer IM, Leuba G, Vernay A, Riederer BM. Protein ubiquitination in different regions of an Alzheimer brain. Abstract No. 68. 2011, USGEB Zürich:35.
52. Singh RP, Sharad S, Kapur S. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. J Ind Acad Clin Med 2004;5:218-25.
53. Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006;75:25-71.
54. Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A, Buée L. Proteasome inhibition and tau proteolysis: an unexpected regulation. FEBS Lett 2005;579:1-5.
55. Navarrete LP, Pérez P, Morales I, Maccioni RB. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies. Curr Alz Res 2011;8:678-85.
56. Cristalli DO, Arnal N, Marra FA, Alaniz MJT, Marra CA. Peripheral markers in neurodegegenrative patients and their first-degree relatives. J Neurol Sci 2012;314:48-56.
57. Di Domenico F, Coccia R, Butterfield DA, Perluigi M. Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits. Biochim Biophys Acta 2011;1814:1785-95.
58. James SA, Volitakis I, Adlard PA, et al. Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Rad Biol Med 2012;52:298-302.
59. Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD. Shift in brain metabolism in late onset Alzheimers's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med 2011;32:247-57.
60. Wong HE, Kwon I. Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregartion and the associated impaired neuronal cell function. Plos ONE 2011;6:e25752.
61. Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer's disease. Biochim Biophys Acta 2012;1822:625-30.
62. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE. The antioxidant -lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003;84:1173-83.
63. das Neves Duarte JM, Kulak A, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psy 2012;71:1006-14.
64. Riederer IM, Moreno Herrero R, Leuba G, Riederer BM. Serial protein labeling with infrared maleimide dyes to identify cysteine modifications. J Proteomics 2008;71:222-30